Novel targeted agents for gastric cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Gastric cancer (GC) remains a leading cause of cancer mortality globally, with limited therapeutic advancements.
• Targeted therapies, including monoclonal antibodies (mAbs) and receptor tyrosine kinase inhibitors (TKIs), are under investigation.
• Trastuzumab is a key example, improving survival in HER2-positive GC, but broader efficacy requires better patient stratification.

Purpose of the Study:

• To highlight the critical need for predictive molecular biomarkers in gastric cancer (GC) treatment.
• To emphasize the limitations of current clinical trial designs lacking patient selection.
• To advocate for biomarker-driven strategies in future GC research and personalized therapy.

Main Methods:

• Review of contemporary advancements in gastric cancer (GC) targeted therapy.
• Analysis of clinical trial outcomes for agents targeting pathways like HER2, VEGF, and mTOR.
• Discussion on the role of molecular biomarkers in patient selection for targeted treatments.

Main Results:

• Trastuzumab demonstrates efficacy in HER2-positive GC, indicating the potential of targeted agents.
• Other targeted agents show marginal benefits, underscoring the need for refined patient selection.
• Current Phase III trials often lack biomarker-based patient stratification, hindering personalized treatment.

Conclusions:

• Effective targeted therapy for gastric cancer (GC) is contingent upon robust patient selection using predictive molecular biomarkers.
• Future clinical trials should integrate biomarker strategies to enable personalized treatment and improve patient outcomes.
• Advancements in understanding GC biology are crucial for developing and applying effective biomarker-based therapies.